PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets recurrent ovarian and endometrial cancers
Disease control OngoingThis early-phase study tests a combination of two oral and intravenous drugs (niraparib and copanlisib) in people whose endometrial, ovarian, peritoneal, or fallopian tube cancer has returned. The main goal is to find the safest dose and understand side effects. About 31 particip…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:08 UTC
-
Immunotherapy duo takes on rare tumors in nationwide trial
Disease control OngoingThis study tests two immunotherapy drugs, nivolumab and ipilimumab, in adults with over 50 types of rare cancers. The goal is to see if this drug combination can shrink tumors or stop them from growing. The trial is no longer enrolling new participants, but results will help guid…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:06 UTC
-
New combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (tremelimumab) to a standard targeted therapy (olaparib) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that still responds to platinum chemotherapy. About 61 adults with these cancers will receive …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:06 UTC
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial is testing the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer. Participants take olaparib for two cycles before their planned surgery to see if it can shrink tumors and is safe. The goal is to find …
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:03 UTC
-
New drug combo shows promise in ovarian cancer trial
Disease control OngoingThis early-stage trial tests whether adding the drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for people with advanced ovarian cancer. About 25 patients with stage III or IV disease will receive the combination before surgery. The go…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for hard-to-treat ovarian cancer: three-drug showdown
Disease control OngoingThis study compares three different combinations of chemotherapy and targeted drugs in 444 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based chemotherapy. The goal is to find which combination best delays cancer growt…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for ovarian cancer: drug combo targets resistant tumors
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The goal is to find the safest dose and see if the combo can shrink tumors or slow their gr…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New hope for Hard-to-Treat ovarian cancer: targeted drug combo under study
Disease control OngoingThis study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Ovarian cancer drug trial tests DNA changes before surgery
Knowledge-focused OngoingThis early-phase trial is testing how the drug adavosertib affects the DNA of tumor cells in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer before they have surgery. The goal is to learn how the drug changes the cancer's DNA, which may help doctors plan bet…
Matched conditions: PRIMARY PERITONEAL HIGH GRADE SEROUS ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 05:49 UTC